<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635074</url>
  </required_header>
  <id_info>
    <org_study_id>HEMAML0036</org_study_id>
    <secondary_id>NCI-2015-01961</secondary_id>
    <secondary_id>35003</secondary_id>
    <secondary_id>IRB-35003</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02635074</nct_id>
  </id_info>
  <brief_title>Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven E. Coutre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ibrutinib when given together&#xD;
      with idarubicin and cytarabine in treating patients with acute myeloid leukemia that has&#xD;
      returned after a period of improvement or has not responded to previous treatment. Ibrutinib&#xD;
      may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.&#xD;
      Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Giving ibrutinib together with idarubicin and cytarabine may&#xD;
      kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      Identify the safety and recommended phase 2 dose of ibrutinib in combination with&#xD;
      idarubicin/cytarabine in relapsed/refractory acute myeloid leukemia (AML).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  Assess the induction response rate (complete remission [CR]/complete remission with&#xD;
           incomplete count [CRi]) of ibrutinib in combination with idarubicin/cytarabine in&#xD;
           relapsed/refractory AML.&#xD;
&#xD;
        -  Assess overall survival of ibrutinib in combination with idarubicin/cytarabine in&#xD;
           relapsed/refractory AML.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of ibrutinib.&#xD;
&#xD;
      INDUCTION: Patients receive ibrutinib orally (PO) once daily (QD) on days 1 to 21, idarubicin&#xD;
      intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to&#xD;
      4.&#xD;
&#xD;
      CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib PO QD on days 1 to 21,&#xD;
      idarubicin IV over 15 minutes on Days 1and 2 and cytarabine IV continuously on days 1-3.&#xD;
      Treatment repeats every 28 days for 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib PO QD on days 1 to 28.&#xD;
      Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    safety&#xD;
  </why_stopped>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction Response Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>The induction Response Rate (CR/CRi) of ibrutinib in combination with idarubicin/cytarabine in relapsed/refractory AML was assessed as the number of participants who achieving a complete response (CR) or complete response with incomplete blood count recovery (CRi), divided by the total number of participants completing induction therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival (OS) was assessed as the number of patients remaining alive 6 months after the initiation of study therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (ibrutinib, idarubicin, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.&#xD;
CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibrutinib, idarubicin, cytarabine)</arm_group_label>
    <other_name>Beta-cytosine arabinoside</other_name>
    <other_name>1-beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-beta-D-arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-pyrimidinone, 4-amino-1-beta-d-arabinofuranosyl</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ibrutinib, idarubicin, cytarabine)</arm_group_label>
    <other_name>Imbruvica</other_name>
    <other_name>BTK Inhibitor PCI-32765</other_name>
    <other_name>PCI-32765</other_name>
    <other_name>CRA-032765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ibrutinib, idarubicin, cytarabine)</arm_group_label>
    <other_name>Idamycin</other_name>
    <other_name>Zavedos</other_name>
    <other_name>4-Demethoxydaunomycin</other_name>
    <other_name>4-Demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Previous morphologically-confirmed diagnosis of acute myeloid leukemia (AML) based on&#xD;
             World Health Organization (WHO) Criteria&#xD;
&#xD;
          -  At least one prior chemotherapy regimen to treat AML&#xD;
&#xD;
          -  Disease relapse or refractory disease as shown by &gt; 5% blasts in the bone marrow (not&#xD;
             attributable to another cause). Administration of hydrea to control high WBC count is&#xD;
             permitted.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, or Karnofsky&#xD;
             Performance Status (KPS) ≥ 60%&#xD;
&#xD;
          -  Life expectancy &gt; 4 weeks&#xD;
&#xD;
          -  Platelet count ≥ 10,000/mm3 within 72 hours of initiating the Induction Cycle&#xD;
             (platelet transfusion support is allowed)&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL within 72 hours of initiating the Induction Cycle&#xD;
&#xD;
          -  Total bilirubin ≤ 2.1 mg/dL within within 72 hours of initiating the Induction Cycle&#xD;
             (EXCEPTION: If elevation is not due to liver dysfunction, and is due primarily to&#xD;
             elevated unconjugated hyperbilirubinemia secondary to Gilbert's syndrome, or hemolysis&#xD;
             of non-hepatic origin)&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) [aspartate aminotransferase (AST) ] ≤&#xD;
             3.0 X upper limit of normal (ULN) within 72 hours of initiating the Induction Cycle&#xD;
&#xD;
          -  Serum glutamic pyruvic transaminase (SGPT) [alanine aminotransferase (ALT)] ≤ 3.0 X&#xD;
             ULN within 72 hours of initiating the Induction Cycle&#xD;
&#xD;
          -  Baseline prothrombin time (PT)/international normalized ratio (INR) ratio &lt; 3 X ULN&#xD;
             within 7 days of initiating the Induction Cycle (for subjects with correctable&#xD;
             coagulation abnormalities, coagulation factor support per institutional standard of&#xD;
             care for AML is allowed)&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) &lt; 3 X ULN within 7 days of initiating the Induction&#xD;
             Cycle (for subjects with correctable coagulation abnormalities, coagulation factor&#xD;
             support per institutional standard of care for AML is allowed)&#xD;
&#xD;
          -  Negative pregnancy test within 14 days prior to study treatment (for Women of&#xD;
             reproductive potential only)&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree (in ICF) to use adequate&#xD;
             contraception (eg, hormonal or barrier methods of birth control; abstinence;&#xD;
             sterilized partner) for the duration of study participation&#xD;
&#xD;
          -  Ability to understand and the willingness to sign the written informed consent&#xD;
             document&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or&#xD;
             investigational therapy) within 2 weeks prior to starting study treatment [EXCEPTION:&#xD;
             Hydroxyurea (hydrea) to control high white blood cell count is permitted]&#xD;
&#xD;
          -  Receiving any other investigational agents within 14 days or 5 effective half lives&#xD;
             (whichever is shorter) prior to 1st dose of ibrutinib&#xD;
&#xD;
          -  Prior treatment with ibrutinib&#xD;
&#xD;
          -  Known unresolved toxicities due to prior anticancer therapy [≥ Grade 2, by Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) v4.03] unless otherwise defined in the&#xD;
             inclusion/exclusion criteria (EXCEPTION: alopecia)&#xD;
&#xD;
          -  Known acute promyelocytic leukemia (French-American-British Class M3-AML)&#xD;
&#xD;
          -  Known active central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Prior bone marrow transplant presenting with active uncontrolled graft vs host disease&#xD;
             (GvHD)&#xD;
&#xD;
          -  Known congenital bleeding disorders, such as hemophilia&#xD;
&#xD;
          -  Known history of stroke or intracranial hemorrhage within 6 months prior to study&#xD;
             treatment&#xD;
&#xD;
          -  Concomitant use of warfarin or other vitamin K antagonists&#xD;
&#xD;
          -  Requires treatment with strong CYP3A inhibitors at the time of study enrollment.&#xD;
             Washout period is 5 effective half-lives is required prior to 1st dose of ibrutinib&#xD;
&#xD;
          -  Requires treatment with strong CYP3A inducers at the time of study enrollment. Washout&#xD;
             period is 5 effective half-lives is required prior to 1st dose of ibrutinib&#xD;
&#xD;
          -  Known active uncontrolled systemic infection&#xD;
&#xD;
          -  Major surgery within 4 weeks of 1st dose of ibrutinib&#xD;
&#xD;
          -  Unable to swallow capsules&#xD;
&#xD;
          -  Known Malabsorption syndrome&#xD;
&#xD;
          -  Known Disease significantly affecting gastrointestinal function&#xD;
&#xD;
          -  Resection of the stomach or small bowel&#xD;
&#xD;
          -  Uncontrolled symptomatic inflammatory bowel disease&#xD;
&#xD;
          -  Ulcerative colitis&#xD;
&#xD;
          -  Bowel obstruction, partial or complete&#xD;
&#xD;
          -  Congestive heart failure with ejection fraction (EF) &lt; 45%&#xD;
&#xD;
          -  Uncontrolled cardiac disease, including uncontrolled cardiac arrhythmia or coronary&#xD;
             artery disease (CAD) with active symptoms due to CAD defined as unstable angina&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to ibrutinib; idarubicin; or cytarabine&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Lactating&#xD;
&#xD;
          -  Known positive HIV&#xD;
&#xD;
          -  Known active hepatitis C&#xD;
&#xD;
          -  Unable to understand the purpose and risks of the study and to provide a signed and&#xD;
             dated informed consent form (ICF) and authorization to use protected health&#xD;
             information (in accordance with national and local subject privacy regulations)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Coutre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Steven E. Coutre</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

